JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waugh, D. J. J.
Right arrow Articles by Abel, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waugh, D. J. J.
Right arrow Articles by Abel, P. W.

Vol. 289, Issue 3, 1419-1426, June 1999

Limitations in Using Peptide Drugs to Characterize Calcitonin Gene-Related Peptide Receptors1

David J. J. Waugh2 , Charles S. Bockman, D. David Smith and Peter W. Abel

Department of Pharmacology (D.J.J.W., C.S.B., D.D.S., P.W.A.) and Department of Biomedical Sciences (D.J.J.W., D.D.S.), Creighton University School of Medicine, Omaha, Nebraska

Calcitonin gene-related peptide (CGRP) is an endogenous vasodilator peptide that produces its effects by activation of CGRP1 and CGRP2 receptor subtypes. These receptor subtypes are characterized in functional studies using the agonist Cys(Acm)2,7-human-alpha -calcitonin gene-related peptide (Cys(ACM)2,7-h-alpha -CGRP), which activates CGRP2 receptors, and the antagonist h-alpha CGRP(8-37) which has a high affinity for CGRP1 receptors and a low affinity for CGRP2 receptors. Our aim was to identify factors that may limit the use of these drugs to characterize CGRP receptor subtypes. We studied CGRP receptors using isolated ring segments of pig coronary and basilar arteries studied in vitro. The affinity of the antagonist h-alpha CGRP(8-37) for inhibiting h-alpha CGRP-induced relaxation of coronary arteries (log10 of the antagonist equilibrium dissociation constant = -5.33) was determined from Schild plots that had steep slopes. Therefore, we used capsaicin to investigate the role of endogenous CGRP in confounding affinity measurements for h-alpha CGRP(8-37). After capsaicin treatment, the slopes of the Schild plots were not different from one, and a higher affinity of h-CGRP(8-37) in blocking relaxation was obtained (log10 of the antagonist equilibrium dissociation constant = -6.01). We also investigated the agonist activity of the putative CGRP2 receptor selective agonist Cys(Acm)2,7-h-alpha CGRP. We found that maximal relaxation of coronary arteries caused by Cys(Acm)2,7-h-alpha CGRP was dependent upon the level of contractile tone induced by KCl. We also determined the KA for Cys(Acm)2,7-h-alpha CGRP and found that the KA (817 nM) was not significantly different from the EC50 (503 nM) for this drug in causing relaxation, indicating that Cys(Acm)2,7-h-alpha CGRP is a partial agonist. Because experimental conditions affect the actions of h-CGRP(8-37) and Cys(Acm)2,7-h-alpha CGRP, the conditions must be carefully controlled to reliably identify CGRP receptor subtypes.

0022-3565/99/2893-1419$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
D. L. Hay, D. R. Poyner, and R. Quirion
International Union of Pharmacology. LXIX. Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor
Pharmacol. Rev., June 1, 2008; 60(2): 143 - 145.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
T. Kawase, K. Okuda, and D. M. Burns
Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)2,7] calcitonin gene-related peptide and CGRP8-37
Am J Physiol Cell Physiol, October 1, 2005; 289(4): C811 - C818.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. L. Hay, G. Christopoulos, A. Christopoulos, D. R. Poyner, and P. M. Sexton
Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes
Mol. Pharmacol., May 1, 2005; 67(5): 1655 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D. M. Burns, L. Stehno-Bittel, and T. Kawase
Calcitonin gene-related peptide elevates calcium and polarizes membrane potential in MG-63 cells by both cAMP-independent and -dependent mechanisms
Am J Physiol Cell Physiol, August 1, 2004; 287(2): C457 - C467.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Hasbak, O. S. Opgaard, K. Eskesen, S. Schifter, H. Arendrup, J. Longmore, and L. Edvinsson
Investigation of CGRP Receptors and Peptide Pharmacology in Human Coronary Arteries. Characterization with a Nonpeptide Antagonist
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
D. R. Poyner, P. M. Sexton, I. Marshall, D. M. Smith, R. Quirion, W. Born, R. Muff, J. A. Fischer, and S. M. Foord
International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors
Pharmacol. Rev., June 1, 2002; 54(2): 233 - 246.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. R. Rorabaugh, M. A. Scofield, D. D. Smith, W. B. Jeffries, and P. W. Abel
Functional Calcitonin Gene-Related Peptide Subtype 2 Receptors in Porcine Coronary Arteries Are Identified as Calcitonin Gene-Related Peptide Subtype 1 Receptors by Radioligand Binding and Reverse Transcription-Polymerase Chain Reaction
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1086 - 1094.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.